UNC Lineberger Comprehensive Cancer Center: Lung Neoplasms trials

The registry lists 27 Lung Neoplasms studies with UNC Lineberger Comprehensive Cancer Center as lead sponsor. 6 are open to participants now and 12 have results posted.

Early Phase 1 1Phase 1 4Phase 2 16No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pharmacologic Therapies to Mitigate Radiation- Associated Heart DiseaseRecruitingNCT07685938Phase 2
• Effects of Infusion Timing on Treatment Response in Solid TumorsRecruitingNCT07630168Phase 2
• PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and SurvivalRecruitingNCT06896162Not applicable
• Autologous CAR T-Cells Targeting the GD2 Antigen for Lung CancerRecruitingNCT05620342Early Phase 1
• UNC Pleural Fluid RegistryRecruitingNCT05620329
• Study of Trilaciclib and LurbinectidinRecruitingNCT05578326Phase 2
• Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®CompletedNCT05011890Not applicableResults posted
• Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxelCompletedNCT02684461Phase 2Results posted
• Cisplatin and Nab-paclitaxel for (N2) Defined NSCLCTerminatedNCT02276560Phase 2Results posted
• Single Arm on the Tolerability of Weekly Nab-paclitaxelCompletedNCT01702844Phase 2Results posted
• Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never SmokersCompletedNCT01344824Phase 2Results posted
• Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing BevacizumabCompletedNCT01262820Phase 2Results posted
• Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLCTerminatedNCT00519831Phase 2Results posted
• Study of Abraxane and Carboplatin to Treat Small Cell Lung CancerTerminatedNCT00454324Phase 2Results posted
• Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLCCompletedNCT00283244Phase 2Results posted
• Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT00280748Phase 2Results posted
• Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLCCompletedNCT00280735Phase 2Results posted
• Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung CancerCompletedNCT00280150Phase 1/2Results posted
• Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLCSuspendedNCT07639242Phase 2
• Abequolixron (RGX-104) and Durvalumab in Lung CancerTerminatedNCT05911308Phase 1
• Risk Stratification for Patients With Hospital-diagnosed Advanced Lung CancerCompletedNCT05722847
• Effect of Incidental Findings Information on Lung Cancer Screening IntentCompletedNCT04432753Not applicable
• Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabSuspendedNCT04266730Phase 1
• Pre-Post Study for Supporting Appropriate Implementation of Lung Cancer ScreeningCompletedNCT03077230Not applicable
• Pilot Study: Utilizing Manometry to Assess Radiation-Induced Changes in Esophageal FunctionTerminatedNCT01992068
• Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) SubjectsCompletedNCT01323062Phase 1
• Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With ChemotherapyWithdrawnNCT00998101Phase 2